Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 14/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.43 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL883831 | 0.91 | EPAS1 (0.47) | PTGDR2PTGDREPAS1 | |
| SCHEMBL2065216 | 0.89 | PTGDR2 (0.49) | PTGDR2PTGDREPAS1 | |
| SCHEMBL2065952 | 0.88 | PTGDR2 (0.55) | PTGDR2PTGDREPAS1 | |
| SCHEMBL2065821 | 0.87 | PTGDR2 (0.47) | PTGDR2EPAS1 | |
| SCHEMBL2066535 | 0.87 | PTGDR2 (0.54) | PTGDR2CHRM1PTGDREPAS1 | |
| SCHEMBL586570 | 0.84 | PTGDR2 (0.54) | PTGDR2PTGDREPAS1 | |
| SCHEMBL883829 | 0.83 | PTGDR2 (0.51) | PTGDR2PTGDREPAS1 | |
| SCHEMBL10121181 | 0.82 | PTGDR2 (0.46) | PTGDR2PTGDREPAS1 | |
| SCHEMBL885402 | 0.82 | PTGDR2 (0.44) | PTGDR2EPAS1 | |
| SCHEMBL883859 | 0.81 | PTGDR2 (0.47) | PTGDR2PTGDREPAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148572-B2 | Compounds | ASTRAZENECA AB (SE) | 2012-04-03 | — | — | US | claimed |
| US-20090192163-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2009-07-30 | — | — | US | claimed |
| US-8148572-B2 | Compounds | ASTRAZENECA AB (SE) | 2012-04-03 | — | — | US | disclosed |
| US-8148572-B2 | Compounds | ASTRAZENECA AB (SE) | 2012-04-03 | — | — | US | disclosed |
| US-20090192163-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2009-07-30 | — | — | US | disclosed |
| US-20090192163-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2009-07-30 | — | — | US | disclosed |
| WO-2007039736-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192163-A1 | Novel Compounds | PAH, PC, DDC | PTGDR2 1000/4885CHRM1 1013/4885PTGDR 859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.